Data Availability StatementThe datasets used and/or analyzed through the current research are available through the corresponding author on reasonable request. by miR-19b-3p mimic transfection and inhibited by miR-19b-3p inhibitor transfection. LncRNA H19 was obviously down-regulated in postmenopausal osteoporosis patients. H19 overexpression significantly decreased cell proliferation and differentiation by down-regulating miR-19b-3p. Moreover, the expression of miR-19b-3p was inhibited, while H19 elvated Rabbit Polyclonal to ARC in 17-estradiol (E2) treated BMSCs in a dose-dependent manner. Conclusion These data were the first to reveal the critical role of H19/miR-19b-3p in postmenopausal osteoporosis, and provided a new therapeutic target for OP. test. Differences between larger groups were analyzed by one-way analysis of variance, followed by Dunnetts test. values less than 0.05 were considered significant. Results MiR-19b-3p is up-regulated in postmenopausal osteoporosis patients and BMP-2-induced BMSCs The expression of miR-19b-3p was first evaluated in the serum of postmenopausal osteoporosis patients and heathy Fraxetin controls by qRT-PCR. As shown in Fig.?1a, the expression of miR-19b-3p was obviously elevated in osteoporosis group as compared with healthy control group (P?P?P?Fraxetin to control group (Fig. ?(Fig.3b,3b, c and d). Open up in another windowpane Fig. 3 MiR-19b-3p increase differentiation of BMSCs. (a) ALP activity was recognized in the supernatant of cells. (b) Proteins manifestation of RUNX2 and COL1A1 had been measured by traditional western blot technique. (c and d) Comparative proteins level was normalized to GAPDH. *P?